Drug Trial Radar · NCT07030478
A Study to Evaluate the Safety and Tolerability of EP0089
Last checked: Nov 19, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Sep 2025
Primary completion
Mar 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Ellipses PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), first-in-class, Phase I/IIa, open-label study designed to evaluate the safety and tolerability of EP0089 (study drug). Study drug will initially be given via intravenous (IV) infusion once every 2 weeks (Q2W), with one treatment cycle defined as 14 days. The study will enroll patients with advanced solid tumours for whom no standard therapy exists or for whom standard therapy has failed. An independent Safety Monitoring Committee (SMC) will review safety data at regular intervals to ensure participant safety and support dose escalation decisions.
Conditions
- Solid Cancers
- Solid Tumours
Interventions
EP0089-101Drug
EP0089 will be initially administered by intravenous (IV) infusion once every 2 weeks (Q2W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of EP0089Time frame: 126 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.